Amgen Inc (AMGN) 173.20 $AMGN Biotech NantKwest Stock

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amgen Inc (AMGN) 173.20 $AMGN

Biotech NantKwest Stock Surges On 1st Day Of Trading
at Investor's Business Daily - 2 hrs 44 mins ago
NantKwest (NK) soared on its first day of trading, after raising $207 million in an upsized initial public offering. NantKwest is in the hot field of immunotherapy, which deploys the patient's own immune system to fight cancer and other diseases....
KITE: 72.02 (+3.16), NK: 36.49 (+36.49), ALXN: 202.29 (+4.19), RCPT: 227.94 (+0.85), AMGN: 173.20 (+7.66), JUNO: 48.75 (+0.95), CELG: 135.65 (+3.09)

Merck Tops on Q2 Earnings & Revenues, Revises Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 28, 9:43AM CDT
Merck (MRK) narrowed and raised its earnings guidance for 2015.
ABT: 50.94 (+0.25), MRK: 57.28 (+0.29), AMGN: 173.20 (+7.66), LLY: 85.52 (+1.37)

Next Resistance Level for Amgen (AMGN) is $170.33
Comtex SmarTrend(R) - Tue Jul 28, 9:31AM CDT
Shares of Amgen (NASDAQ:AMGN) opened today above their pivot of $163.55 and have already reached the first level of resistance at $167.93. Analysts will be watching for a cross of the next upside pivot targets of $170.33 and $177.11.
AMGN: 173.21 (+7.67)

Gliosarcoma Pipeline Review H1 2015 - Analysis of 7 Companies & 11 Drug Profiles
M2 - Tue Jul 28, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mmkt6/gliosarcoma) has announced the addition of the "Gliosarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Burzynski Research Institute, Inc. - Celgene Corporation - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Sanofi Drug Profiles - alisertib - Antineoplaston Therapy - CC-122 - DNX-2401 - indoximod - lonafarnib - Oncolytic Virus to Target IL-12 for Oncology - plerixafor - rilotumumab - SGT-53 - Stem Cell Therapy for Glioma For more information visit http://www.researchandmarkets.com/research/5m...liosarcoma
MRK: 57.28 (+0.29), NLNK: 53.43 (+2.46), AMGN: 173.21 (+7.67), CELGZ: 2.03 (+0.03)

3 Questions to Ask Ahead of Amgen's Second-Quarter Earnings Release
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 27, 5:26PM CDT
Source: Amgen via Flickr. Things have really come together nicely for biotech blue-chip stock Amgen over the last couple of years. Following a decade where its share price had essentially gone nowhere despite aggressive share buybacks, the...
AMGN: 173.21 (+7.67)

Amgen Announces Webcast of 2015 Second Quarter Financial Results
PR Newswire - Mon Jul 27, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, July 30, 2015, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
AMGN: 173.21 (+7.67)

Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval
Brian Feroldi, The Motley Fool - Motley Fool - Mon Jul 27, 1:56PM CDT
Healthcare giants  Regeneron Pharmaceuticals   and  Sanofi SA (ADR) treated their investors to great news over the weekend as the companies announced that they won FDA approval of their highly anticipated cholesterol-lowering medication Praluent. ...
AMGN: 173.21 (+7.67), SNY: 53.59 (+0.26), REGN: 556.30 (+16.27)

4 Stocks Spiking on Unusual Volume
at The Street - Mon Jul 27, 1:39PM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
SWI: 38.32 (+0.75), ITEK: 17.42 (+0.66), AMGN: 173.21 (+7.67), URI: 67.16 (+2.00)

Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 158.84 (-0.65), BIIB: 317.95 (+8.52), LGND: 106.29 (+3.74), AMGN: 173.21 (+7.67), REGN: 556.30 (+16.27), EXEL: 5.48 (+0.04), CELG: 135.65 (+3.09)

Global Colorectal Cancer Drugs Market 2015-2019
M2 - Mon Jul 27, 9:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xdrzz/global_colorectal) has announced the addition of the "Global Colorectal Cancer Drugs Market 2015-2019" report to their offering. The global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019. Biologics are rapidly becoming the treatment of choice for colorectal cancer. Biologics are targeted therapy, which act only on the malignant cells and do not attack the healthy cells. The major biologics used for treating colorectal cancer include Erbitux (cetuximab), Zaltrap (ziv-Aflibercept), Avastin (bevacizumab), and Vectibix (panitumumab). These biologics together accounted for the major share of the market, and the same trend is expected to continue during the forecast period. According to the report, colorectal cancers cannot be cured by the currently available therapeutic options. In addition, if it has not metastasized, surgery would be the only option. The chances of cancer recurring near the place of origin are high. The currently available branded and generic drugs are indicated only for off-label treatment use. However, these drugs have many side effects. Hyperbilirubinemia, gastrointestinal perforation, coagulopathy, cardiotoxicity, hemorrhage, hepatotoxicity, neutropenia, proteinuria, thrombocytopenia, ischemia, soft tissue toxicity, pulmonary fibrosis, and increased mortality are some of the significant adverse side effects. Thus, a drug maker has opportunities to exploit and seek a favorable position in the market by addressing these issues. Further, the report states that many branded drugs available in the market have lost their patents or are expected to lose it during the forecast period. This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer. Based on the type of molecule, the market is grouped into two categories: - Biologics - Small molecules Based on the route of administration, the market is grouped into two categories: - Oral - Parenteral Key Vendors - Amgen - Bayer - Bristol-Myers Squibb - F. Hoffmann-La Roche - Merck Serono Other Prominent Vendors - Accord Healthcare - Advenchen Laboratories - Aeterna Zentaris - AstraZeneca - Bavarian Nordic - Biothera - Boehringer Ingelheim - Daiichi Sankyo - Debiopharm - Eisai - Eli Lilly - Immodulon Therapeutics - Mologen - Mylan - Nektar Therapeutics - Oncothyreon - Otsuka Pharmaceutical - Precision Biologics - Sun Pharmaceutical - Symphogen - Taiho - Takeda - Teva - ThromboGenics - Xbiotech - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/5x...colorectal
MRK: 57.28 (+0.29), AMGN: 173.21 (+7.67), LLY: 85.52 (+1.37), BMY: 64.50 (+0.20), NKTR: 12.94 (+0.52)

Stock Market News for July 27, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:10AM CDT
Declines in biotech and commodity related stocks dragged benchmarks down to on the red on Friday
BIIB: 317.95 (+8.52), AMZN: 526.75 (-4.66), MON: 101.43 (-0.03), COP: 52.62 (+1.97), AMGN: 173.21 (+7.67), XOM: 82.22 (+2.96), SLB: 82.68 (+0.92), CELG: 135.65 (+3.09), RIG: 14.08 (+0.97), GILD: 112.40 (+1.86), DD: 55.93 (-0.80), PX: 115.07 (+3.25), CVX: 92.19 (+3.05), DOW: 46.86 (+1.23), REGN: 556.12 (+16.09)

Medullary Thyroid Cancer - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 5:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ldtm6m/medullary_thyroid) has announced the addition of the "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" report to their offering. "Medullary Thyroid Cancer Global Clinical Trials Review, H1, 2015" provides data on the Medullary Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Medullary Thyroid Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Medullary Thyroid Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Medullary Thyroid Cancer Therapeutics Clinical Trials - AstraZeneca PLC - Exelixis, Inc. - Eisai Co., Ltd. - Sino Biopharmaceutical Limited - Sanofi - Immunomedics, Inc. - Globeimmune, Inc. - EANM Research Ltd. - Bayer AG - Amgen Inc. - National Cancer Institute - University of Kentucky - University of Wisconsin Madison - Garden State Cancer Center - University of Texas M. D. Anderson Cancer Center - University of Southern California - Sidney Kimmel Comprehensive Cancer Center - University of Washington - Medical University of Vienna - Leiden University Medical Center For more information visit http://www.researchandmarkets.com/research/ld...ry_thyroid
IMMU: 2.60 (-1.11), AZN: 32.85 (+0.14), AMGN: 173.21 (+7.67), EXEL: 5.48 (+0.04)

Global Glomerulonephritis Clinical Trials Review 2015
M2 - Mon Jul 27, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hjc7bk/glomerulonephritis) has announced the addition of the "Glomerulonephritis Global Clinical Trials Review, H1, 2015" report to their offering. Glomerulonephritis Global Clinical Trials Review, H1, 2015" provides data on the Glomerulonephritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Glomerulonephritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Glomerulonephritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Glomerulonephritis Therapeutics Clinical Trials - Regulus Therapeutics Inc. - GlaxoSmithKline plc - Celldex Therapeutics, Inc. - Anthera Pharmaceuticals Inc. - Pharmalink AB - Osprey Pharmaceuticals U.S.A., Inc. - La Jolla Pharmaceutical Company - Daiichi Sankyo Company, Limited - Bristol-Myers Squibb Company - Amgen Inc. - The National Institute of Diabetes and Digestive and Kidney Diseases - Chinese PLA General Hospital - Chinese University of Hong Kong - Columbia University - Hospital Authority - Mayo Clinic For more information visit http://www.researchandmarkets.com/research/hj...onephritis
ANTH: 11.14 (-0.01), CLDX: 24.74 (+0.43), AMGN: 173.21 (+7.67), RGLS: 8.91 (+0.23), GSK: 41.70 (+0.10), BMY: 64.50 (+0.20)

Otic Pharma Appoints Gregory J. Flesher as Chief Executive Officer
PR Newswire Europe - Mon Jul 27, 2:30AM CDT
Otic Pharma Ltd, a privately held pharmaceutical company focused on developing innovative therapies for ear, nose, and throat disorders, today announced the appointment of Gregory J. Flesher as chief executive officer and member of the company's board of directors.
AMGN: 173.21 (+7.67)


FDA OKs breakthrough cholesterol drug for high-risk patients
By MATTHEW PERRONE - AP - Fri Jul 24, 5:31PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades.
PFE: 35.26 (+0.92), AMGN: 173.21 (+7.67), REGN: 556.12 (+16.09)

Look for Shares of Amgen to Potentially Rebound after Yesterday's 3.36% Sell Off
Comtex SmarTrend(R) - Fri Jul 24, 4:53PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $157.21 to a high of $163.73. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $161.47 on volume of 4.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 173.21 (+7.67)

SmarTrend Watching for Potential Rebound in Shares of Amgen After 3.36% Loss
Comtex SmarTrend(R) - Fri Jul 24, 4:52PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $157.21 to a high of $163.73. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $161.47 on volume of 4.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 173.21 (+7.67)

Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK
at Investor's Business Daily - Fri Jul 24, 4:24PM CDT
Praluent, the new cholesterol-busting drug from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), was granted FDA approval Friday, but for a slightly more limited patient pool than some had hoped. Regeneron stock closed down 2.7% to 541.85 on the...
ESPR: 69.53 (-2.12), MDCO: 33.65 (+0.26), PFE: 35.26 (+0.92), AMGN: 173.21 (+7.67), SNY: 53.59 (+0.26), REGN: 556.12 (+16.09)

Earnings Growth Hard to Come By - Earnings Preview
Sheraz Mian - Zacks Investment Research - Fri Jul 24, 2:35PM CDT
Earnings Growth Hard to Come By - Earnings Preview
WFM: 40.89 (+0.73), ROP: 164.69 (+0.44), FB: 95.26 (+1.09), PFE: 35.26 (+0.92), IP: 48.73 (+1.37), AMGN: 173.21 (+7.67), COP: 52.62 (+1.97), XOM: 82.22 (+2.96), UPS: 100.40 (+5.28), MRK: 57.28 (+0.29), EXPE: 106.86 (+1.94), DD: 55.93 (-0.80), PG: 80.49 (+0.52), CVX: 92.19 (+3.05), MA: 95.26 (+0.87)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LONGi's Four Paths to Global Green Development

Updated Category News Views 41

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 328

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 71

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 199

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 167

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 258

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 157

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 152

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 249

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading

Top 5 Most Recently Viewed Articles

Trade Developments Impacting Global Stocks and Currencies

Updated Category News Views 225

Trade Developments Impacting Global Stocks During the latest trading session in Asia, futures for the S&P 500 and Nasdaq 100 showed positive momentum, increasing by 0.5% and 0.6% respectively. This positive trend comes after Friday's historic closing levels. The surge in optimism can be largely attributed to developments surrounding a trade agreement between the US and...

Continue Reading
Subaru Launches Gear for Good Initiative for Youth Soccer Growth

Updated Category News Views 152

Subaru Champions Youth Soccer with Gear for Good Initiative Subaru of America is proud to announce its engaging initiative, Gear for Good, aimed at nurturing the budding talent in youth soccer. This project represents Subaru's unwavering commitment to community involvement, ensuring that every child has access to the necessary tools to pursue their passion for soccer....

Continue Reading
Discover Nykredit's Upcoming Mortgage Bond Auction Insights

Updated Category News Views 306

Nykredit's Mortgage Bond Auction Overview Nykredit Realkredit A/S, a prominent financial institution, is organizing an exciting auction designed for interested investors. This event aims to enhance participation in the mortgage bond market, making it a notable opportunity for those seeking investment options. What to Expect at the Auction Scheduled for a future date, the...

Continue Reading
Paperclip Partners with Apis Productions for Robust Data Security

Updated Category News Views 106

Paperclip Collaborates with Apis Productions for Enhanced Security In an exciting new development, Paperclip, Inc. (OTCMKTS: PCPJ) has announced its partnership with Apis Productions to launch cutting-edge data security solutions. This collaboration focuses on integrating Paperclip’s innovative SAFE encryption technology within Apis Productions’ insurance technology...

Continue Reading
Medical Imaging Equipment Services Market Set for Growth Surge

Updated Category News Views 91

Overview of the Medical Imaging Equipment Services Market The Medical Imaging Equipment Services Market is set for a period of substantial growth, with projections indicating an increase from USD 60 billion in 2024 to USD 85 billion by 2031. This growth trajectory correlates with a compound annual growth rate (CAGR) of 5.0%. Several factors are contributing to this steady...

Continue Reading